1. text

difficulties in Industrial Synthesis of Ogleron (CAS:2212020-52-3) and Selection Criteria for Three Key Intermediates

core keywords: Ogleron synthesis process, impurity control of Ogleron intermediate, 4-bromo -3-fluoro -2-methylaniline procurement standard, 5-bromo -4-fluoro -1H-indazole isomer control, 5-bromo -1-cyclopropyl -4-fluoro -1H-indazole mass production supply, GLP1 oral drug raw material production raw material

opening

oral GLP-1 small molecule drug Ogleron (CAS 2212020-52-3) commercial expansion stage, the vast majority of API manufacturers will encounter three major problems: low yield of indazole ring synthesis, excessive isomer impurities, upstream raw material supply. The quality bottleneck of the whole synthesis route is concentrated in the three-stage fluorinated aromatic intermediates: 4-bromo-3-fluoro-2-methylaniline, 5-bromo-4-fluoro-1H-indazole, 5-bromo-1-cyclopropyl-4-fluoro-1H-indazole. The purity of the intermediate, the type of impurities, and the batch stability directly determine the subsequent API purification cost and the declared pass rate. From the perspective of industrial production, this paper disassemps the selection index, synthesis function and quality control standard of the three intermediates to provide selection reference for the R & D and procurement team of pharmaceutical enterprises.

H2: Why is the industrial production of Ogleron demanding three fluorinated intermediates?

1. The uniqueness of the molecular structure limits the GLP-1 receptor binding region of the non-alternative raw material Ogrelon depends on the 4-fluorine, 5-bromine, N1 cyclopropyl trisubstituted indazole skeleton, any substituent position shift will generate inactive by-products, there is no alternative low-cost general-purpose intermediate on the market.

2. Trace isomer impurities cannot be removed at the back end. Isomeric impurities brought by aniline raw materials will run through the whole process of ring closing, alkylation and coupling. API recrystallization alone cannot be removed, which will lead to substandard toxicological tests and ICH impurity limits.

3. Large-scale synthesis of raw material moisture, residual metal has a hard threshold palladium catalytic coupling step on the bromide intermediate heavy metals, moisture sensitivity is very high, low standard raw materials will greatly reduce the reaction conversion rate, pull up the overall production cost.

H2: Quality Control Points and Division Details of Three Intermediates in Ogleron Process Chain

table: Three intermediate production risk, quality control indicators, process positioning differentiation table.

Table

h3:4-bromo -3-fluoro -2-methyl aniline (127408-03-1): the first barrier of source quality control

as the starting aromatic material for the entire route, the substitution site purity of the aniline is the starting point for all quality control. Many small chemical suppliers only provide crude products, ortho-and meta-brominated impurities cannot be separated, and the ring-formation of indazole isomers is difficult to separate. Attention to procurement by pharmaceutical companies: suppliers shall provide nuclear magnetic resonance maps and HPLC impurity distribution maps to prove that there are no positional isomers; It is suitable for impurity traceability verification in advance in the small-scale test and pilot test stages.

H3:5-bromo -4-fluoro -1H-indazole (1082041-85-7): key intermediate for success or failure of cyclosynthesis process

the preparation of the precursor aniline by diazotization ring closure, the process difficulty lies in controlling the selectivity of the ring closure. If the purity of the raw material is insufficient, a large amount of 5-fluoro-4-bromo isomer will be generated, and the impurity will not participate in the subsequent cyclopropylation reaction, and eventually become an unknown impurity of API. Our supporting scheme: the use of low-temperature controlled recrystallization process, isomer ND (not detected), no additional purification of customers, saving pilot man-hours.

H3:5-bromo -1-cyclopropyl -4-fluoro -1H-indazole (2490501-34-1):API coupling special advanced block

this is the closest intermediate to the finished product of Ogleron, and the bromine atom serves as the leaving group for the cross-coupling reaction. If the batch-to-batch residual non-ring-based core, the coupling reaction conversion rate decreased by more than 40%, greatly increasing the cost of commercial production. Commercialization advantages: can directly provide tons of cGMP batches, a full set of declaration documents to support FDA, EMA API declaration, suitable for clinical phase III, ready for commercialization of pharmaceutical companies.

H2: 3 supply chain pits that pharmaceutical companies often step on when purchasing Ogleron intermediates

1. Purchase multiple suppliers in stages, impurity standards are not uniform, and process parameters fluctuate greatly between batches;

2. Only focus on purity values, ignoring isomers, residual solvents, heavy metal subdivision detection items;

3. The purity of the small test sample is up to standard, the mass production batch process shrinks, and there is a risk of excessive impurities and production interruption.

H2: What production pain points can be solved by one-stop intermediate supply?

1. Three intermediates self-production integration, unified impurity control standards, impurity traceability integrity, reduce the difficulty of API purification;

2. Simultaneously provide gram-level samples, kilogram pilot test and ton-level commercial production capacity, and seamlessly switch from research and development to mass production;

3. Complete set of application materials: COA, SDS, nuclear magnetic resonance, liquid phase map, impurity research report, shorten the application period;

4. Hazardous chemicals comply with cold chain export, stable delivery period, to avoid the risk of overseas raw materials supply.

H2:FAQ Procurement & Process Questions and Answers

q1: Do the three intermediates have to be purchased simultaneously for the pilot test of Ogleron? A1: It is recommended to purchase the whole set. The impurity systems of the raw materials of the three different suppliers are inconsistent, which will increase the unknown impurities and increase the difficulty of process optimization; the impurity spectrum of the integrated self-produced raw materials is unified and the process is more stable.

Q2: Which impurity needs to be detected most when purchasing 5-bromo-4-fluoro-1H-indazole? A2: The isomer of 6-bromo-4-fluoro-1H-indazole should be detected preferentially, which cannot be removed in the following steps, and is the main rejection risk point of API declaration.

Q3: Do the intermediate purity standards need to be distinguished between laboratory test and commercial mass production? A3: Distinguish. Small-scale research and development can be relaxed to more than 99.0%; Clinical and commercial production must implement 99.2%/99.5%/99.6% graded high purity standards to meet ICH reporting requirements.

Q4: Is it possible to purchase only the final 5-bromo-1-cyclopropyl-4-fluoro-1H-indazole, omitting the first two steps of raw material procurement? A4: Yes, but the upstream purchased parent nuclear intermediates cannot be completely traced to the impurities, and the reporting stage will lack complete process impurity research data, increasing the risk of review.

Q5: What are the special requirements for the storage and transportation of the three intermediates? A5: All of them should be sealed and stored dry in the dark to avoid high temperature; Brominated fluorinated heterocycles are controlled hazardous chemicals, and professional hazardous packaging and compliance customs declaration documents are required for export.

Conclusion

the core bottleneck of the commercial expansion of Ogleron is not the design of drug molecule synthesis, but the purity control and stable supply chain of the three fluoroindazole series intermediates. 4-bromo -3-fluoro -2-methyl aniline, 5-bromo -4-fluoro -1H-indazole, 5-bromo -1-cyclopropyl -4-fluoro -1H-indazole through the whole synthesis process, the source impurities will be amplified step by step to affect the quality of API. Our integrated self-produced full-chain intermediates, strict control of isomers, heavy metals, residual solvents, for GLP-1 oral drug research and development and mass production enterprises to provide stable, in line with the reporting standards of raw materials solutions. If you need impurity maps, sample samples and mass production quotations, you can consult the docking process specialist through official website.